OrganiGram (TSE:OGI) and Emblem (CVE:EMC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of current recommendations for OrganiGram and Emblem, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
OrganiGram | 4 | 2 | 2 | 0 | 1.75 |
Emblem | 0 | 0 | 0 | 0 | N/A |
OrganiGram presently has a consensus price target of C$3.77, indicating a potential upside of 26.44%. Given OrganiGram's higher possible upside, research analysts clearly believe OrganiGram is more favorable than Emblem.
Profitability
This table compares OrganiGram and Emblem's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
OrganiGram | N/A | N/A | N/A |
Emblem | N/A | N/A | N/A |
Valuation and Earnings
This table compares OrganiGram and Emblem's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
OrganiGram | C$72.40 million | 12.32 | $-340,283,853.00 | C($1.14) | -2.62 |
Emblem | $5.71 million | 43.02 | $-24,806,020.00 | ($0.19) | -9.89 |
Emblem has lower revenue, but higher earnings than OrganiGram. Emblem is trading at a lower price-to-earnings ratio than OrganiGram, indicating that it is currently the more affordable of the two stocks.
Summary
OrganiGram beats Emblem on 4 of the 7 factors compared between the two stocks.